


# PRODUCT INFORMATION



## Ozagrel

Item No. 70515

**CAS Registry No.:** 82571-53-7  
**Formal Name:** 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-2E-propenic acid  
**Synonym:** OKY-046  
**MF:** C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>  
**FW:** 228.3  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 275 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Ozagrel is supplied as a crystalline solid. A stock solution may be made by dissolving the ozagrel in the solvent of choice, which should be purged with an inert gas. Ozagrel is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of ozagrel in these solvents is approximately 1 mg/ml.

Ozagrel is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ozagrel should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Ozagrel has a solubility of approximately 1 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Inhibition of thromboxane synthase (TXAS), especially in human platelets, has been a clinical objective for many years. 1-Alkyl (N-alkyl)-imidazole derivatives have been recognized as TXAS inhibitors since the early 1980s.<sup>1-3</sup> Ozagrel is a 1-alkyl imidazole derivative that acts as a selective inhibitor of TXAS with an IC<sub>50</sub> of 11 nM. The beneficial effects of TXAS inhibition by ozagrel include improved motor coordination after experimental stroke<sup>4</sup> and antihypertensive effects in spontaneously hypertensive rats.<sup>5</sup>

### References

1. Iizuka, K., Akahane, K., Momose, D., *et al.* Highly selective inhibitors of thromboxane synthase. 1. Imidazole derivatives. *J. Med. Chem.* **24**, 1139-1148 (1981).
2. Wright, W.B., Tomcufcik, A.S., Chan, P.S., *et al.* Thromboxane synthase inhibitors and antihypertensive agents. 4,N-[(1H-imidazol-1-yl)alkyl] derivatives of quinazoline-2,4(1H,3H)-diones, quinazolin-4(3H)-ones, and 1,2,3-benzotriazin-4(3H)-ones. *J. Med. Chem.* **30**, 2277-2283 (1987).
3. Wright, W.B., Jr., Press, J.B., Chan, P.S., *et al.* Thromboxane synthetase inhibitors and antihypertensive agents. 1. N-[(1H-imidazol-1-yl)alkyl]aryl amides and N-[(1H-imidazol-1,2,4-triazol-1-yl)alkyl]aryl amides. *J. Med. Chem.* **29**, 523-530 (1986).
4. Ichikawa, K., Tazawa, S., Hamano, S., *et al.* Effect of ozagrel on locomotor and motor coordination after transient cerebral ischemia in experimental animal models. *Pharmacology* **59**, 257-265 (1999).
5. Press, J.B., Wright, W.B., Jr., Chan, P.S., *et al.* Thromboxane synthetase inhibitors and antihypertensive agents. 2. N-[(1H-imidazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones and N-[(1H-1,2,4-triazol-1-yl)alkyl]-1H-isoindole-1,3(2H)-diones as unique antihypertensive agents. *J. Med. Chem.* **29**(5), 816-819 (1986).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/19/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM